The latest research by U.S Food and Drug Administration approved a breakthrough drug Palbociclib for treating breast cancer. Palbociclib is the first drug to be approved by FDA to treat women with advanced breast cancer. The study has been done on 165 post-menopausal breast cancer patients with advanced ER+, HER2- disease who had not received any systemic therapy for their metastatic disease. This drug signals a new treatment strategy to control tumour and help to increase the time before it aggravates.
Palbociclib attacks by targeting (CDK4/6) responsible for cell growth by inhibiting cells to divide rapidly. It has significantly increased the progression-free survival for patients suffering with breast cancer. As per Jonsson Cancer Center report Palbociclib is the benchmark for postmenopausal women with ER+/HER2- metastatic breast cancer.